Cardiac implications for the use of β2-adrenoceptor agonists for the management of muscle wasting

Authors


Discipline of Medicine, The University of Queensland, The Prince Charles Hospital, Chermside, Queensland 4032, Australia. E-mail: p.molenaar@mailbox.uq.edu.au

Abstract

There are proposals for the implementation of β2-adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that β2-adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart β2-adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients.

British Journal of Pharmacology (2006) 147, 583–586. doi:10.1038/sj.bjp.0706670

Ancillary